

New prospects in cellular therapy

Corporate Symposium

June 24, 2007, 3:00–5:00 pm

Sydney Convention Center, Darling Harbour, Bayside Auditorium A, Sydney, Australia

3:00 Introduction

Jeffrey S. Miller, MD, Minneapolis, USA

3:05 Preemptive CD8⁺ T cell–depleted donor lymphocyte infusion following nonmyeloablative stem cell transplantation (NMT) for acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS)

C. S. Chen, MD, PhD, National University Hospital Singapore, Singapore

3:25 The role of NK cells and their receptors in cancer and hematologic malignancies

Jeffrey S. Miller, MD, University of Minnesota, Minneapolis, MN, USA

3:45 Treatment of severe systemic lupus erythematosus patients with autologous peripheral blood stem cell transplantation

Daobin Zhou, MD, Peking Union Medical College Hospital, Beijing, China

4:05 Endothelial progenitor cells for vascular medicine

Takayuki Asahara, MD, PhD, Kobe Institute of Biomedical Research and Innovation, Kobe, Japan

4:25 Panel discussion: New prospects in cellular therapy

Rationale for holding the seminar

This seminar is designed for investigators from different disciplines, such as immunologists, hematologists, and oncologists, as well as for investigators working in the field of regenerative medicine. Innovative approaches for graft manipulation or donor lymphocyte infusions by means of cell separation have been transferred from preclinical to clinical settings, where first data look very promising. The choice of well-known speakers and the topics they address are intended to stimulate an open discussion on innovative protocols and therapeutic options in infectious diseases, cancer and regenerative medicine.

Learning objectives

- Outline the different potential applications for cellular products in stem cell transplantation.
- Discuss the therapeutic potential of different cell types, either as DLI or after graft manipulation.
- Review preclinical and first clinical experiences with the use of stem cells in peripheral artery disease.

Target audience

This program is designed to meet the educational needs of hematologists, immunologists, oncologists, and others. Technicians, scientists, and physicians specializing in transplantation, internal medicine, hematology, and oncology will also benefit from attending the seminar.

The CliniMACS® System components (Reagents, Tubing Sets, Instruments and PBS/EDTA Buffer) are manufactured and controlled under an ISO 13485 certified quality system.

In Europe, the CliniMACS System components are available as CE-marked medical devices.

In the USA, the CliniMACS System components including the CliniMACS Reagents are available for use only under an approved Investigational New Drug (IND) application or Investigational Device Exemption (IDE).

CliniMACS® MicroBeads are for research use only and not for use in humans.

MACS and CliniMACS are registered trademarks of Miltenyi Biotec GmbH.

CliniMACS®
Cell Selection System

